Arcutis logo.png
Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock
August 02, 2022 16:02 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) --  Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing...
Arcutis logo.png
Arcutis to Host Investor Conference Call Today to Discuss the FDA Approval of ZORYVE™ (roflumilast) Cream 0.3% for Plaque Psoriasis
August 01, 2022 07:30 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial biopharmaceutical company focused on developing meaningful...
Arcutis logo.png
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
June 06, 2022 07:30 ET | Arcutis Biotherapeutics, Inc.
Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59.2% of patients treated with vehicle...
Graphic 2_Time and Treatments
CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
May 25, 2022 10:33 ET | Arcutis Biotherapeutics, Inc.
Seborrheic dermatitis is a chronic, inflammatory skin disease that affects more than 10 million people in the U.S.Survey found that, among adults with seborrheic dermatitis who use treatments, only...
Arcutis logo.png
Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022 16:01 ET | Arcutis Biotherapeutics, Inc.
Increasing commercial preparations in advance of our Prescription Drug User Fee Act (PDUFA) action date of July 29, 2022 for roflumilast cream for the treatment of plaque psoriasis in adults and...
Arcutis logo.png
Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis
April 06, 2022 08:00 ET | Arcutis Biotherapeutics, Inc.
Topline data anticipated in late Q3/early Q4A total of 432 subjects are enrolled in the ARRECTOR studyArcutis progressing topical roflumilast in four dermatological indicationsOver 3 million patients...
Arcutis logo.png
Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts
March 28, 2022 08:00 ET | Arcutis Biotherapeutics, Inc.
Differentiated profile of topical roflumilast aligned with unmet needs in multiple inflammatory dermatosesWell-prepared for the Company’s potential first launch ahead of PDUFA target action date of...
Arcutis logo.png
Arcutis to Host Investor Day on March 28
March 21, 2022 08:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis logo.png
Arcutis to Present at Upcoming Investor Conference
March 02, 2022 05:30 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 22, 2022 16:01 ET | Arcutis Biotherapeutics, Inc.
Received U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis in adults and adolescentsCompleted enrollment...